Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 18/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.33 |
| ▸ | KDM5C | P41229 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324743 | 0.75 | NR1H2 (0.70) | NR1H2ROCK1 | |
| SCHEMBL5606354 | 0.73 | NR1H2 (0.64) | NR1H2ROCK1KDM5B | |
| SCHEMBL17321388 | 0.73 | NR1H2 (0.67) | NR1H2ROCK1 | |
| SCHEMBL1683479 | 0.71 | NR1H2 (0.76) | NR1H2ROCK1KDM5B | |
| SCHEMBL1683503 | 0.71 | NR1H2 (0.49) | NR1H2ROCK1 | |
| SCHEMBL4225009 | 0.70 | NR1H2 (0.67) | NR1H2ROCK1 | |
| SCHEMBL5606212 | 0.69 | NR1H2 (0.46) | NR1H2ROCK1 | |
| SCHEMBL5596556 | 0.69 | NR1H2 (0.46) | NR1H2ROCK1KDM5B | |
| SCHEMBL5606208 | 0.68 | NR1H2 (0.46) | NR1H2ROCK1 | |
| SCHEMBL1683444 | 0.68 | KDR (0.50) | NR1H2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543009-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | NR1H2 2346/4885ROCK1 548/4885KDM5A 1190/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | NR1H2 2146/4885ROCK1 546/4885KDM5A 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.